Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) Reimburse with clinical criteria and/or conditions Complete
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Reimburse with clinical criteria and/or conditions Complete
Campral Acamprosate calcium Alcohol Abstinence List with clinical criteria and/or conditions Complete
Campral Acamprosate calcium Alcohol Abstinence N/A Complete
Tudorza Genuair Aclidinium bromide Chronic Obstructive Pulmonary Disease List with criteria/condition Complete
Duaklir Genuair Aclidinium bromide/formoterol fumarate dihydrate Chronic obstructive pulmonary disease List with clinical criteria and/or conditions Complete
Humira Adalimumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Humira Adalimumab Arthritis, Psoriatic List with clinical criteria and/or conditions Complete
Humira Adalimumab Ankylosing spondylitis (AS) List with clinical criteria and/or conditions Complete
Humira Adalimumab Crohn's disease List with clinical criteria and/or conditions Complete